University of GenevaSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.
Tag Archive for: Fianancing
Romi - adobe stock.comBelgian lysosomal storage disease specialist Azafaros BV has added a new lead investor to its portfolio. In addition to €25m Series A leader Forbion, Jeito Captial co-led a €132m Series B round aimed at advancing two pivotal trials of Azafaros‘ lead compound nizabagloustat (AZ-3102).
Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development.